Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan

Jung-An Lin, Yeu-Chin Chen, Shin-Nan Cheng, Peng-Jen Chen, Heng-Cheng Chu, Tsai-Yuan Hsieh, Yu-Lueng Shih

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/purpose: Chronic hepatitis C virus (HCV) infection is a major cause of morbidity and mortality in patients with hemophilia. However, the efficacy and safety of pegylated interferon (PEG-IFN) plus ribavirin (RBV) for hemophilic patients with chronic HCV infection in Taiwan are still unknown. The aim of this study is to report the efficacy and safety of PEG-IFN plus RBV in a single center in Taiwan. Methods: In an open-label single-treatment one-arm cohort study, 12 hemophilic patients with elevated alanine aminotransferase level more than two times the upper limit of normal for more than 3 months received 180μg/week of PEG-IFN-α-2a plus RBV 1000-1200mg/day at a cut-off value of 75kg. The duration of treatment was 48 weeks for patients with HCV Genotype 1/4 infection and 24 weeks for patients with HCV Genotype 2/3 infection. Efficacy of therapy was expressed as sustained virological response (SVR). Results: Eight patients achieved SVR (66.7%). The SVR rates were 57%, 100%, 100%, and 0% for patients with HCV Genotypes 1, 2, 3, and 4 infection, respectively. Adverse events (AEs) developed in 10 patients (83.3%). Severe thrombocytopenia developed in one patient. However, the patient did not suffer from severe bleeding. Conclusion: Our study shows that the SVR rates are similar in hemophilic and nonhemophilic patients with chronic HCV infection who receive PEG-IFN-α-2a plus RBV in Taiwan. The rate of AEs also resembled other studies in nonhemophilic patients in Taiwan. No patient suffered from severe bleeding. However, large-scale, well-conducted studies are still needed to verify the treatment efficacy and safety. © 2013.
Original languageEnglish
Pages (from-to)727-733
Number of pages7
JournalJournal of the Formosan Medical Association
Volume113
Issue number10
DOIs
Publication statusPublished - 2014
Externally publishedYes

Keywords

  • Hemophilia
  • Hepatitis C
  • Pegylated interferon
  • Ribavirin
  • Viral response
  • alanine aminotransferase
  • bilirubin
  • creatinine
  • peginterferon alpha2a
  • ribavirin
  • serum albumin
  • alpha interferon
  • antivirus agent
  • macrogol derivative
  • recombinant protein
  • adult
  • alanine aminotransferase blood level
  • anemia
  • Article
  • bleeding
  • chronic hepatitis
  • clinical article
  • clinical trial
  • cohort analysis
  • coughing
  • decompensated liver cirrhosis
  • drug dose reduction
  • drug efficacy
  • drug induced headache
  • drug safety
  • drug withdrawal
  • fatigue
  • female
  • flu like syndrome
  • follow up
  • hemophilia
  • hepatitis C
  • Hepatitis C virus genotype 1
  • Hepatitis C virus genotype 2
  • Hepatitis C virus genotype 3
  • Hepatitis C virus genotype 4
  • human
  • human tissue
  • insomnia
  • liver cell carcinoma
  • lung tuberculosis
  • major depression
  • male
  • middle aged
  • myalgia
  • neutropenia
  • prospective study
  • pruritus
  • sepsis
  • sustained virological response
  • Taiwan
  • thrombocytopenia
  • treatment duration
  • treatment response
  • blood
  • complication
  • drug combination
  • drug effects
  • genetics
  • genotype
  • hemophilia A
  • Hepacivirus
  • Hepatitis C, Chronic
  • procedures
  • treatment outcome
  • virology
  • virus load
  • Adult
  • Alanine Transaminase
  • Antiviral Agents
  • Cohort Studies
  • Drug Therapy, Combination
  • Genotype
  • Hemophilia A
  • Humans
  • Interferon-alpha
  • Male
  • Middle Aged
  • Polyethylene Glycols
  • Recombinant Proteins
  • Treatment Outcome
  • Viral Load

Fingerprint Dive into the research topics of 'Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan'. Together they form a unique fingerprint.

  • Cite this